Fig. 5From: Guidelines for molecular testing in non-small cell lung cancer – recommendations from the Brazilian Society of PathologyFrom diagnostic to biomarker, several decisions should be made by the MDT with participation of the pathologist. In the current scenarios, at least 3 main options are available, based on availability, cost, and possibility of reimbursementBack to article page